+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Dyslipidemia and atherogenic risk in patients with rheumatoid arthritis



Dyslipidemia and atherogenic risk in patients with rheumatoid arthritis



Clinica E Investigacion en Arteriosclerosis 28(3): 123-131



Dyslipidaemia is one of the main risk factors for atherosclerotic cardiovascular disease. Patients with rheumatoid arthritis have 2-3 times more cardiovascular risk, which is partly due to the pattern of lipids which increase the atherogenic index. A descriptive, cross-sectional, observational and prospective study was conducted on 82 patients, selected for their lipid profile. Variables associated with the disease and the drugs used were recorded. Atherogenic risk was calculated, with Chi square being used for categorical variables, and the Mann-Whitney test for the continuous ones. The dyslipidaemia frequency was 54.9%. The most frequent age range of dyslipidaemia was between 51 and 60 years. Patients with type i obesity had a higher frequency of dyslipidaemia. Less dyslipidaemia was found with a lower rate of disease activity. Patients with cyclic citrullinated anti-peptide antibodies and positive rheumatoid factor, erythrocyte sedimentation rate>13mm or CRP>2mg/L had a higher frequency of dyslipidaemia. The mean Castelli atherogenic index was 4.36, the index of Kannel was 2.59, and triglycerides/HDL-c ratio was 3.83.Patients with dyslipidaemia showed a higher frequency of positive rheumatoid factor (P=.0008), and those patients who were taking hydroxychloroquine had a lower frequency of dyslipidaemia P=.03. Patients with rheumatoid arthritis have a pro-atherogenic lipid profile. It is important to know this and treat it to reduce cardiovascular risk.

(PDF emailed within 0-6 h: $19.90)

Accession: 057672755

Download citation: RISBibTeXText

PMID: 27026386

DOI: 10.1016/j.arteri.2016.02.002


Related references

Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship?. Current Allergy and Asthma Reports 15(2): 497, 2015

Prevalence of dyslipidemia and elevated cardiovascular risk in patients with rheumatoid arthritis. Medicina 73(1): 26-30, 2013

Clinical decision rules in rheumatoid arthritis: Do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register. Annals of the Rheumatic Diseases 61(12): 1085-1089, December, 2002

Atherogenic dyslipidemia and residual risk in patients with ischemic stroke. Revista de Neurologia 60(9): 429-430, 2016

Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 45(5): 1429-1436, 2014

Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Research and Therapy 11(2): R37, 2009

Dyslipidemia in patients with rheumatoid arthritis. Clinica E Investigacion en Arteriosclerosis 28(3): 141-142, 2017

Cardiovascular risk in patients with atherogenic dyslipidemia. Perspective of primary care physicians. Avanza study. Atherosclerosis 263: E281-E281, 2018

Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR/EULAR criteria for rheumatoid arthritis. Rheumatology 53(4): 771-771, 2014

Risk of rheumatoid arthritis development in patients with unclassified arthritis according to the 2010 ACR/EULAR criteria for rheumatoid arthritis. Rheumatology 52(7): 1265-1270, 2013

Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. Clinica E Investigacion en Arteriosclerosis 26(6): 274-284, 2015

Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. American Journal of Cardiology 100(10): 1511-1516, 2007

Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. Current Medical Research and Opinion 26(12): 2833-2839, 2011

Inflammatory and atherogenic lipoprotein markers in patients with rheumatoid arthritis. Circulation 100(18 SUPPL ): I 813, Nov 2, 1999

Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vascular Health and Risk Management 3(6): 845-852, 2008